Cargando…
Postinjection delirium/sedation syndrome in a transgender man undergoing hormone therapy
BACKGROUND: Long-acting injectable medications have become an important tool in the treatment of schizophrenia and schizoaffective disorder due to the high rates of medication nonadherence. Olanzapine long-acting injection (OLAI) is a useful therapeutic option for patients who have good tolerability...
Autores principales: | Gerving, Joshua, Walser, Heather, Kelly, Anne C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association of Psychiatric Pharmacists
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405634/ https://www.ncbi.nlm.nih.gov/pubmed/36071735 http://dx.doi.org/10.9740/mhc.2022.08.263 |
Ejemplares similares
-
Postinjection Delirium/Sedation Syndrome with Olanzapine Depot Injection
por: Sarangula, Sadhvi Mythili, et al.
Publicado: (2016) -
Is Low Body Mass Index a Risk Factor for Postinjection Delirium/Sedation Syndrome?
por: Punnoose, Zarine Maria, et al.
Publicado: (2017) -
Postinjection delirium/sedation syndrome with long-acting olanzapine pamoate in a middle-aged female
por: Upadhyay, Apoorva, et al.
Publicado: (2017) -
Postinjection delirium/sedation syndrome in patients with schizophrenia receiving olanzapine long-acting injection: results from a large observational study
por: Meyers, Kristin J., et al.
Publicado: (2017) -
Postinjection Muscle Fibrosis from Lupron
por: Everest, Erica, et al.
Publicado: (2015)